Skip to content

Internet Explorer is no longer supported by this website.

For optimal browsing we recommend using Chrome, Firefox or Safari.
Heart icon (animated) heart icon (static)

Jump to:

Our Commitment to the Communities Most Impacted by COVID-19
Our Commitment to the Communities Most Impacted by COVID-19
Our Commitment to the Communities Most Impacted by COVID-19

e are investigating multiple doses and dosing regimens of our investigational COVID-19 vaccine candidate to evaluate long-term efficacy.

The Phase 3 clinical trial for our single-dose COVID-19 vaccine candidate, known as ENSEMBLE, enrolled approximately 45,000 participants. We are actively enrolling participants in our ENSEMBLE 2 Phase 3 clinical trial examining a two-dose COVID-19 vaccine regimen.

Driven by our company Credo, we have a responsibility to put the needs and well-being of the patients, families, and communities we serve first. The COVID-19 pandemic is significantly impacting communities of color and older populations and we must ensure these populations are included in the ENSEMBLE studies as study volunteers. Including a diverse and representative group of study volunteers as we are determining the efficacy (whether it works) and safety of an investigational vaccine for the prevention of COVID-19 will ensure that we learn how differences like age, race and ethnicity may impact these measures.

Enrollment Details for the ENSEMBLE Phase 3 Clinical Trial Evaluating a Single-Dose Vaccine Candidate

expand

This site uses cookies as described in our Cookie Policy. Please click the "Accept" button or continue to use our site if you agree to our use of cookies.
Close cookie banner icon
Back to top
You are now leaving jnj.com. The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.
Continue